Search

Your search keyword '"Amy, L."' showing total 3 results
3 results on '"Amy, L."'

1. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Author

Magbanua, Mark Jesus M, Brown Swigart, Lamorna, Ahmed, Ziad, Sayaman, Rosalyn W, Renner, Derrick, Kalashnikova, Ekaterina, Hirst, Gillian L, Yau, Christina, Wolf, Denise M, Li, Wen, Delson, Amy L, Asare, Smita, Liu, Minetta C, Albain, Kathy, Chien, A Jo, Forero-Torres, Andres, Isaacs, Claudine, Nanda, Rita, Tripathy, Debu, Rodriguez, Angel, Sethi, Himanshu, Aleshin, Alexey, Rabinowitz, Matthew, Perlmutter, Jane, Symmans, W Fraser, Yee, Douglas, Hylton, Nola M, Esserman, Laura J, DeMichele, Angela M, Rugo, Hope S, and van 't Veer, Laura J

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer Genomics, Clinical Trials and Supportive Activities, Cancer, Genetics, Women's Health, Breast Cancer, Human Genome, Clinical Research, Good Health and Well Being, Humans, Female, Breast Neoplasms, Triple Negative Breast Neoplasms, Circulating Tumor DNA, Neoadjuvant Therapy, Clinical Relevance, Antineoplastic Combined Chemotherapy Protocols, Biology, Receptor, ErbB-2, Receptor, erbB-2, circulating tumor DNA, gene expression, neoadjuvant chemotherapy, pathologic complete response, receptor subtype, residual cancer burden, Neurosciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment via non-invasive tumor burden assessment. To investigate subtype-specific differences in the clinical significance and biology of ctDNA shedding, we perform serial personalized ctDNA analysis in hormone receptor (HR)-positive/HER2-negative breast cancer and triple-negative breast cancer (TNBC) patients receiving neoadjuvant chemotherapy (NAC) in the I-SPY2 trial. ctDNA positivity rates before, during, and after NAC are higher in TNBC than in HR-positive/HER2-negative breast cancer patients. Early clearance of ctDNA 3 weeks after treatment initiation predicts a favorable response to NAC in TNBC only. Whereas ctDNA positivity associates with reduced distant recurrence-free survival in both subtypes. Conversely, ctDNA negativity after NAC correlates with improved outcomes, even in patients with extensive residual cancer. Pretreatment tumor mRNA profiling reveals associations between ctDNA shedding and cell cycle and immune-associated signaling. On the basis of these findings, the I-SPY2 trial will prospectively test ctDNA for utility in redirecting therapy to improve response and prognosis.

Published
2023

2. Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors

Author

Jaime M. Guidry Auvil, Vicki Huff, Yussanne Ma, Richard A. Moore, Julie M. Gastier-Foster, Denise Brooks, Jeffrey S. Dome, Daniela S. Gerhard, Jing Ma, Yueh-Yun Chi, Marco A. Marra, Jacqueline E. Schein, Malcolm A. Smith, Oliver A. Hampton, Elizabeth J. Perlman, Ariadne H. A. G. Ooms, Andrew J. Mungall, Amy L. Walz, Nicole Ross, Qing-Rong Chen, Reanne Bowlby, Chih Hao Hsu, Chunhua Yan, Daoud Meerzaman, Charles G. Mullighan, David A. Wheeler, Samantha Gadd, Nadereh Jafari, Cu Nguyen, Ying Hu, and Pathology

Subjects
Ribonuclease III, Cancer Research, DGCR8, Mesenchyme, Loss of Heterozygosity, Nerve Tissue Proteins, Bioinformatics, Polymorphism, Single Nucleotide, Wilms Tumor, Article, Loss of heterozygosity, Perilobar nephrogenic rest, microRNA, medicine, Humans, Drosha, Homeodomain Proteins, biology, RNA-Binding Proteins, Histology, Wilms' tumor, Cell Biology, medicine.disease, Gene Expression Regulation, Neoplastic, MicroRNAs, medicine.anatomical_structure, Oncology, Favorable histology, Cancer cell, Mutation, biology.protein, Cancer research, Homeobox, Neoplasm Recurrence, Local
Abstract

SummaryWe report the most common single-nucleotide substitution/deletion mutations in favorable histology Wilms tumors (FHWTs) to occur within SIX1/2 (7% of 534 tumors) and microRNA processing genes (miRNAPGs) DGCR8 and DROSHA (15% of 534 tumors). Comprehensive analysis of 77 FHWTs indicates that tumors with SIX1/2 and/or miRNAPG mutations show a pre-induction metanephric mesenchyme gene expression pattern and are significantly associated with both perilobar nephrogenic rests and 11p15 imprinting aberrations. Significantly decreased expression of mature Let-7a and the miR-200 family (responsible for mesenchymal-to-epithelial transition) in miRNAPG mutant tumors is associated with an undifferentiated blastemal histology. The combination of SIX and miRNAPG mutations in the same tumor is associated with evidence of RAS activation and a higher rate of relapse and death.

Published
2015
Full Text
View/download PDF

3. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages

Author

Roger A. Sabbadini, Amy L. Cavalli, Yiling Lu, Shuangxing Yu, John A. Vekich, Barbara Visentin, Kelli Moreno, Vikas Kundra, Hassan Hall, Rosalia Matteo, Gordon B. Mills, Bradley J. Sibbald, and William A. Garland

Subjects
Cancer Research, Angiogenesis, medicine.drug_class, Enzyme-Linked Immunosorbent Assay, medicine.disease_cause, Monoclonal antibody, Neovascularization, 03 medical and health sciences, chemistry.chemical_compound, Mice, 0302 clinical medicine, Antibody Specificity, Sphingosine, Cell Line, Tumor, medicine, Animals, Humans, Neoplasm Invasiveness, Sphingosine-1-phosphate, 030304 developmental biology, Cell Proliferation, 0303 health sciences, biology, Neovascularization, Pathologic, organic chemicals, Cancer, Antibodies, Monoclonal, Endothelial Cells, Cell Biology, Neoplasms, Experimental, medicine.disease, Molecular biology, 3. Good health, CHEMBIO, chemistry, Oncology, Tumor progression, 030220 oncology & carcinogenesis, Cancer research, biology.protein, lipids (amino acids, peptides, and proteins), Female, Antibody, medicine.symptom, Lysophospholipids, Carcinogenesis
Abstract

SummaryS1P has been proposed to contribute to cancer progression by regulating tumor proliferation, invasion, and angiogenesis. We developed a biospecific monoclonal antibody to S1P to investigate its role in tumorigenesis. The anti-S1P mAb substantially reduced tumor progression and in some cases eliminated measurable tumors in murine xenograft and allograft models. Tumor growth inhibition was attributed to antiangiogenic and antitumorigenic effects of the antibody. The anti-S1P mAb blocked EC migration and resulting capillary formation, inhibited blood vessel formation induced by VEGF and bFGF, and arrested tumor-associated angiogenesis. The anti-S1P mAb also neutralized S1P-induced proliferation, release of proangiogenic cytokines, and the ability of S1P to protect tumor cells from apoptosis in several tumor cell lines, validating S1P as a target for therapy.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results